In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials ...

GlobalData is the parent company of Clinical Trials Arena. Amgen and AstraZeneca are also investigating Tezspire in other ...

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

The global oral solid dosage pharmaceutical formulation market is poised for remarkable expansion, with projections indicating a growth from USD 629,582.6 million in 2024 to USD 895,636.0 million by ...

AstraZeneca is holding crisis talks with the Chinese authorities after the arrest of its boss in the country. The ...

AstraZeneca is building a US$1.5 billion manufacturing facility in Tuas South, Singapore, which will create over 800 jobs.

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you ...

Chinese authorities detained the head of AstraZeneca’s China business last week, a move that threatens to dim foreign ...

Pharmaceutical giant AstraZeneca has confirmed that Leon Wang, the head of its China operations, had been detained.

These could enable new approaches to precise drug delivery across the field of genetic medicines whilst underpinning our business model with passive income from licensing. We look forward to updating ...